Related Experiment Video
Updated: Apr 4, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Cancer Genomic Medicine for Urological Malignancies in Japan
Yusuke Sato1,2, Yoichi Fujii2, Haruki Kume2
1Department of Urology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Abstract:
Cancer is a disease caused by genomic alterations, and identifying the profile of genetic changes in each cancer leads to the optimal choice of treatment, that is, precision medicine. In Japan, comprehensive genomic profiling tests were covered by insurance in June 2019, and cancer genomic medicine was fully implemented in clinical practice. In the field of urological malignancies, the approval of olaparib for metastatic castration-resistant prostate cancer with BRCA1/2 mutations has led to the practical application of cancer genomic medicine in many cases. However, various challenges exist in its implementation and clinical utilization. This review outlines cancer genomic medicine in urological malignancies, focusing on the types and characteristics of genetic tests performed in clinical settings, as well as the accessibility of treatments based on their results.
Related Concept Videos
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

